Elena Elimova, MD, discusses data from a HERIZON-GEA-01 PD-L1 subgroup analysis in HER2-positive gastroesophageal adenocarcinoma.
Examining the Benefits of a Zanidatamab Combo in HER2+ Gastroesophageal Adenocarcinoma
Zanidatamab plus tislelizumab and chemotherapy improved PFS and OS in HER2-positive mGEA regardless of PD-L1 status by TAP score or CPS.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
4
The OncFive: Top Oncology Articles for the Week of 7/12
5